SUPN — Supernus Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapHigh Flyer

Annual income statement for Supernus Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	520	580	667	608	662
Cost of Revenue
Gross Profit	468	505	580	524	593
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	347	494	621	613	580
Operating Profit	174	86	46.1	-5.27	81.7
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	169	73.2	60.7	2.77	97.9
Provision for Income Taxes
Net Income After Taxes	127	53.4	60.7	1.32	73.9
Net Income Before Extraordinary Items
Net Income	127	53.4	60.7	1.32	73.9
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	127	53.4	64.3	1.32	73.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	2.48	1.28	1.04	0.197	1.44